Regeneron vs. Omicron; The Fed’s New Plan; The Boss’ Half-a-Billion
Squawk Pod
English - December 16, 2021 18:01 - 27 minutes - 25.2 MB - ★★★★ - 450 ratingsInvesting Business News Business News leadership health entrepreneurship business productivity startups finance interview entrepreneur fitness Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Regeneron Pharmaceuticals is developing new antibodies that work against the omicron variant of Covid-19, after the company confirmed that its current cocktail has diminished potency against the heavily mutated strain. CEO Leonard Schleifer says Regeneron plans to conduct trials on the new antibodies in the first quarter of 2022. The Federal Reserve’s move to accelerate its taper but not yet move the needle on interest rates has left market analysts in disagreement over whether it was the right call and how it could impact stocks. CNBC’s Steve Liesman breaks down how the markets are reacting to the Federal Reserve’s policy pivot on Wednesday. Plus, Bruce Springsteen has reportedly sold his music rights to Sony Music Entertainment in what could be the biggest deal ever struck for a single artist’s work.
In this episode:
Leonard Schleifer, @Regeneron
Meg Tirrell, @megtirrell
Steve Liesman, @steveliesman
Joe Kernen, @JoeSquawk
Becky Quick, @BeckyQuick
Andrew Ross Sorkin, @andrewrsorkin
Klaire Odumody, @klairemarie